TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood

Leukemia Research

Volumn 39, Issue 10, 2015, Pages 1103-1108

  Coutinho, Diego F ^a   Monte Mór, Bárbara C R ^a   Vianna, Danielle T ^a,b   Rouxinol, Soraia T ^b   Batalha, Anna Beatriz W ^c   Bueno, Ana Paula S ^c   Boulhosa, Alice M ^c   Fernandez, Teresa S ^a   Pombo de Oliveira, Maria S ^a   Gutiyama, Luciana M ^a   Abdelhay, Eliana ^a   Zalcberg, Ilana R ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b HOSPITAL FEDERAL DA LAGOA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Epigenetics; Myelodysplastic syndrome; Pediatrics; Refractory cytopenia of childhood; TET2

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA BINDING PROTEIN; MICRORNA; MIRN22 MICRORNA, HUMAN; ONCOPROTEIN; TET2 PROTEIN, HUMAN; TRANSCRIPTOME;

ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOPENIA; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MALE; METHYLATION; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TET2 GENE; VIRUS INFECTION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CASE CONTROL STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; INFANT; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOSINE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; MALE; MICRORNAS; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; TRANSCRIPTOME;

EID: 84941317845     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.07.005     Document Type: Article

References (34)

1. Elias H.K., Schinke C., Bhattacharyya S., Will B., Verma A., Steidl U. Stem cell origin of myelodysplastic syndromes. Oncogene 2013, 10.1038/onc.2013.520.
2. Malcovati L., Hellström-Lindberg E., Bowen D., Adès L., Cermak J., Del Cañizo C., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013, 122:2943-2964. 10.1182/blood-2013-03-492884.
3. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N. Engl. J. Med. 2009, 361:1872-1885. 10.1056/NEJMra0902908.
4. Elghetany M.T. Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. Arch. Pathol. Lab. Med. 2007, 131:1110-1116. 10.1043/1543-2165(2007)131[1110:MSICAC]2.0.CO;2.
5. Hasle H., Niemeyer C.M., Chessells J.M., Baumann I., Bennett J.M., Kerndrup G., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17:277-282. 10.1038/sj.leu.2402765.
6. Hasle H., Niemeyer C.M. Advances in the prognostication and management of advanced MDS in children. Br. J. Haematol. 2011, 154:185-195. 10.1111/j.1365-2141.2011.08724.x.
7. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 2010, 363:2424-2433. 10.1056/NEJMoa1005143.
8. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69. 10.1038/nature10496.
9. Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 2013, 45:1232-1237. 10.1038/ng.2731.
10. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 2013, 369:2391-2405. 10.1056/NEJMoa1312542.
11. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. 10.1182/blood-2013-08-518886.
12. Haferlach T., Nagata Y., Grossmann V., Okuno Y., Bacher U., Nagae G., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28:241-247. 10.1038/leu.2013.336.
13. Shen L., Wu H., Diep D., Yamaguchi S., D'Alessio A.C., Fung H.-L., et al. Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 2013, 153:692-706. 10.1016/j.cell.2013.04.002.
14. Wu H., Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 2014, 156:45-68. 10.1016/j.cell.2013.12.019.
15. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147. 10.1182/blood-2009-03-210039.
16. Langemeijer S.M.C., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842. 10.1038/ng.391.
17. Cimmino L., Abdel-Wahab O., Levine R.L., Aifantis I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011, 9:193-204. 10.1016/j.stem.2011.08.007.
18. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843. 10.1038/nature09586.
19. Pronier E., Almire C., Mokrani H., Vasanthakumar A., Simon A., da Costa Reis Monte Mor B., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555. 10.1182/blood-2010-12-324707.
20. Kudo Y., Tateishi K., Yamamoto K., Yamamoto S., Asaoka Y., Ijichi H., et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012, 103:670-676. 10.1111/j.1349-7006.2012.02213.x.
21. Coutinho D.F., Diniz C., Filgueiras R.L.D., Baptista R.L.R., Ayres-Silva J.P., Monte-Mór B.C.R., et al. Case report: a novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia. Genet. Mol. Res. 2013, 12:5858-5862. 10.4238/2013.November.22.13.
22. Cheng J., Guo S., Chen S., Mastriano S.J., Liu C., D'Alessio A.C., et al. An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Rep. 2013, 5:471-481. 10.1016/j.celrep.2013.08.050.
23. Song S.J., Ito K., Ala U., Kats L., Webster K., Sun S.M., et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87-101. 10.1016/j.stem.2013.06.003.
24. Zhang P., Huang B., Xu X., Sessa W.C. Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem. Biophys. Res. Commun. 2013, 437:368-373. 10.1016/j.bbrc.2013.06.082.
25. Hasegawa D., Manabe A., Kubota T., Kawasaki H., Hirose I., Ohtsuka Y., et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br. J. Haematol. 2005, 128:805-812. 10.1111/j.1365-2141.2005.05392.x.
26. Vidal D.O., Paixão V.A., Brait M., Souto E.X., Caballero O.L., Lopes L.F., et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk. Res. 2007, 31:175-181. 10.1016/j.leukres.2006.06.013.
27. Olk-Batz C., Poetsch A.R., Nollke P., Claus R., Zucknick M., Sandrock I., et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 2011, 117:4871-4880. 10.1182/blood-2010-08-298968.
28. Wlodarski M.W., Motter J., Gorr T.A., Olk-Batz C., Hasle H., Dworzak M., et al. Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. Blood 2011, 118:4490-4491. 10.1182/blood-2011-07-370684.
29. Rocquain J., Carbuccia N., Trouplin V., Raynaud S., Murati A., Nezri M., et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010, 10:401. 10.1186/1471-2407-10-401.
30. Solary E., Bernard O.A., Tefferi A., Fuks F., Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014, 28:485-496. 10.1038/leu.2013.337.
31. Walter M.J., Shen D., Shao J., Ding L., White B.S., Kandoth C., et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013, 27:1275-1282. 10.1038/leu.2013.58.
32. Liu X., Zhang G., Yi Y., Xiao L., Pei M., Liu S., et al. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk. Lymphoma 2013, 54:2466-2473. 10.3109/10428194.2013.778408.
33. Scopim-Ribeiro R., Machado-Neto J.A., de Melo Campos P., Silva C.A.M., Favaro P., Lorand-Metze I., et al. Ten-Eleven-Translocation 2 (TET2) is downregulated in myelodysplastic syndromes. European Journal of Haematology 2014, 10.1111/ejh.12445.
34. Chim C.S., Wan T.S., Fung T.K., Wong K.F. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J. Clin. Pathol. 2010, 63:942-946. 10.1136/jcp.2010.080218.